Canaccord Genuity lifts 10x Genomics price target to $100
Canaccord Genuity maintained a Buy rating on 10x Genomics and raised its price target from $60.00 to $100.00 per share.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
According to Newsmetry API, citing Benzinga’s ratings data, Canaccord Genuity maintained its Buy rating on 10x Genomics shares.
The broker also increased its price target from $60.00 to $100.00 per share. The information was published on October 12, 2026, at 17:17 GMT.
why it matters
The higher target signals an updated analyst valuation for 10x Genomics, while the Buy recommendation was unchanged. The company’s shares trade under the TXG ticker.
instruments
sources
- 10x Genomics Price Target Raised to $100.00/Share From $60.00 by Canaccord Genuity — Newsmetry API, 12 October 2026 at 17:17 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗